An enzyme involved in the formation of the amyloid-beta protein associated with Alzheimers disease can also alter the mechanism by which signals are transmitted between brain cells , the disruption of which can cause seizures.
These findings from researchers at the MassGeneral Institute for Neurodegenerative Disorders may explain the increased incidence of seizures in Alzheimers patients and suggest that potential treatments that block this enzyme called beta-secretase may alleviate their occurrence.
Alzheimer's disease is characterized by plaques within the brain of the toxic amyloid-beta protein. Amyloid-beta is formed when the larger amyloid precursor protein (APP) is clipped by two enzymes BACE and gamma-secretase which releases the amyloid-beta fragment.
Signaling impulses in nerve cells are transmitted via voltage-gated sodium channels, structures on the cell membrane that transmit electrochemical signal by admitting charged sodium particles into the cells interior. Sodium channels consist of an alpha subunit, which makes up the body of the channel, and one or two beta subunits that help to regulate the channels activity.
Previous studies from Kovacs team and others showed that the BACE and gamma-secretase enzymes that release amyloid-beta from APP also act on the beta2 subunit of neuronal sodium channels. The current study was designed to examine how this processing of the beta2 subunit may alter neuronal function.
Lead author Doo Yeon Kim, PhD, and colleagues first confirmed that the beta2 subunit, similar to APP, can be acted on by BACE and gamma-secretase, releasing a portion of the beta2 molecule from the cell membrane.
A series of experiments using brain tissue from animal models and from Alzheimers patients revealed the following series of cellular events: Elevated levels of the free beta2 segment within the cell appear to increase production of the alpha subunits, but
those molecules are not incorporated into new sodium channels on the cell surface. The resulting deficit of membrane sodium channels inhibits the passage of neuronal signals into and through the cells.
Neuronal sodium-channel dysfunction is known to cause seizures in both mice and humans. In a supplement to the current paper the investigators present evidence that sodium channel metabolism is altered in the brains of Alzheimers patients compared with non-demented individuals of similar age.
Our study suggests that the BACE inhibitors currently being developed to reduce amyloid-beta generation in Alzheimers disease patients may also help prevent seizures by alleviating disrupted neural activity, Kovacs explains. However, complete inhibition of BACE activity could interfere with the enzymes normal regulation of sodium channels, so therapeutic strategies using those inhibitors will need to be carefully designed. Related medicine news :1
. Testing genes for disease does not cause harm to children of people with Alzheimers 2
. Age-Dependent Alterations Not Specific For Alzheimers Disease 3
. Killing two birds (cholesterol and Alzheimers disease) with the same stone 4
. Exposure To High Aluminum Levels In Tap Water Lead To Rare Form Of Alzheimers5
. Sugar variant may make a world of difference to Alzheimers disease6
. Cancer Causing Protein May Heal Alzheimers7
. Emotional Stress Could Be a Factor in Causing Alzheimers: Study8
. Alzheimers Incidence is Set to Quadruple by 20509
. GAB2-A New Alzheimers Gene Identified10
. Reduced Oxygen to the Brain Increases Alzheimers Risk in Stroke Victims11
. Magnets to the rescue of Alzheimers patients